HBW
CLBT icon

Hazlett, Burt & Watson’s Cellebrite CLBT Stock Holding History

Hazlett, Burt & Watson’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15K Hold
1,000
– – ﹤0.01% 637
2026
Q1 		$14K Hold
1,000
– – ﹤0.01% 640
2025
Q4 		$18K Hold
1,000
– – 0.01% 609
2025
Q3 		$19K Buy
+1,000
New +$15.7K 0.01% 567

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
PP
Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NTCM
Nine Ten Capital Management Chicago, Illinois $321M AUM 44.58% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Hazlett, Burt & Watson's CLBT Position: Q2 2026 in Review

Hazlett, Burt & Watson held its Cellebrite (CLBT) position steady in Q2 2026 at 1,000 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #637.

Hazlett, Burt & Watson first reported a position in CLBT in Q3 2025 and has held it in 4 quarters since. The position peaked at $19K in Q3 2025. 200 funds tracked by Wall St. Rank hold CLBT as of Q2 2026.

  • Hazlett, Burt & Watson held 1,000 shares of Cellebrite worth $15K as of Q2 2026.
  • Hazlett, Burt & Watson left its Cellebrite share count unchanged in Q2 2026.
  • Cellebrite made up ﹤0.01% of Hazlett, Burt & Watson's portfolio in Q2 2026, its #637 holding.
  • Hazlett, Burt & Watson first reported a position in Cellebrite in Q3 2025 and has held it in 4 quarters since.
  • Hazlett, Burt & Watson's Cellebrite position peaked at $19K in Q3 2025.
  • 200 funds tracked by Wall St. Rank held Cellebrite as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.